Conventional small molecule approaches have struggled to address genetic defects and complex disease mechanisms, leaving ...

Dr Reddy's Laboratories has received an establishment inspection report from the USFDA for its Srikakulam facility. The report classifies the site as 'Voluntary Action Indicated', meaning no immediate ...

Expands commercial readiness and diagnostic, manufacturing footprintAppoints new leadership in commercial strategy and technical ...

"We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Officer of Abeona. "James has ...

SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong ...

Check IPO allotment status, refund process, and latest GMP trends—act now to stay updated on the listing date!

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced ...

The IPO of Canara HSBC Life Insurance Company Limited was a book-built issue worth Rs 2,517.50 crore. It was entirely an ...

Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the ...